MXPA06015037A - Composiciones que contienen aequorina y metodos para usar las mismas. - Google Patents
Composiciones que contienen aequorina y metodos para usar las mismas.Info
- Publication number
- MXPA06015037A MXPA06015037A MXPA06015037A MXPA06015037A MXPA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A MX PA06015037 A MXPA06015037 A MX PA06015037A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- aequorin
- same
- containing compositions
- oralleviating
- Prior art date
Links
- 108010000239 Aequorin Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/872,795 US20060229243A1 (en) | 2004-06-21 | 2004-06-21 | Aequorin-containing compositions and methods of using same |
| PCT/US2005/021770 WO2006010004A2 (en) | 2004-06-21 | 2005-06-21 | Aequorin-containing compositions and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06015037A true MXPA06015037A (es) | 2007-07-11 |
Family
ID=35785748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06015037A MXPA06015037A (es) | 2004-06-21 | 2005-06-21 | Composiciones que contienen aequorina y metodos para usar las mismas. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20060229243A1 (https=) |
| EP (2) | EP2545934B1 (https=) |
| JP (1) | JP4971150B2 (https=) |
| KR (1) | KR101213555B1 (https=) |
| CN (1) | CN1997383B (https=) |
| AU (1) | AU2005265266B2 (https=) |
| BR (1) | BRPI0512392B1 (https=) |
| CA (1) | CA2571542C (https=) |
| CY (1) | CY1114307T1 (https=) |
| DK (1) | DK1768691T3 (https=) |
| ES (1) | ES2422173T3 (https=) |
| IL (1) | IL180195A (https=) |
| MX (1) | MXPA06015037A (https=) |
| NZ (1) | NZ552274A (https=) |
| PL (1) | PL1768691T3 (https=) |
| PT (1) | PT1768691E (https=) |
| SG (1) | SG153848A1 (https=) |
| SI (1) | SI1768691T1 (https=) |
| WO (1) | WO2006010004A2 (https=) |
| ZA (1) | ZA200610688B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
| GB0625678D0 (en) | 2006-12-21 | 2007-01-31 | Lux Biotechnology Ltd | Composition and method for detection of demineralisation |
| BRPI0909435A2 (pt) | 2008-03-11 | 2017-06-13 | Quincy Bioscience Llc | composição e método para tratar de um sintoma ou distúrbio associado com o desequilíbrio do cálcio, uso da apoequorina, e, apoaequorina |
| JP2010143860A (ja) * | 2008-12-19 | 2010-07-01 | Chisso Corp | タンパク質の安定化剤 |
| US20110130336A1 (en) * | 2009-10-16 | 2011-06-02 | Quincy Bioscience, Llc | Method of treating ischemic injury using apoaequorin |
| US9316588B2 (en) * | 2010-12-24 | 2016-04-19 | Otsuka Pharmaceutical Co., Ltd. | Bioassay method for detecting physiologically active substance |
| KR102009932B1 (ko) * | 2011-11-15 | 2019-08-12 | 퀸시 바이오사이언스 엘엘씨 | 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린 |
| GB201700317D0 (en) | 2017-01-09 | 2017-02-22 | Calcivis Ltd | Detection device |
| USD1042180S1 (en) | 2020-05-28 | 2024-09-17 | Calcivis Limited | Dental detection device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001240855A (ja) * | 2000-03-01 | 2001-09-04 | Masashi Sugimoto | 生物発光方法及び発光物品 |
| US6800492B2 (en) * | 2000-06-01 | 2004-10-05 | Institute Pasteur | Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level |
| WO2001096361A1 (en) * | 2000-06-12 | 2001-12-20 | University Of Maryland Biotechnology Institute | Method of controlling the binding of calmyrin to presenilin |
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
-
2004
- 2004-06-21 US US10/872,795 patent/US20060229243A1/en not_active Abandoned
-
2005
- 2005-06-21 SG SG200904273-0A patent/SG153848A1/en unknown
- 2005-06-21 JP JP2007518179A patent/JP4971150B2/ja not_active Expired - Fee Related
- 2005-06-21 NZ NZ552274A patent/NZ552274A/en not_active IP Right Cessation
- 2005-06-21 US US11/571,043 patent/US7671015B2/en not_active Expired - Lifetime
- 2005-06-21 KR KR1020077001461A patent/KR101213555B1/ko not_active Expired - Lifetime
- 2005-06-21 BR BRPI0512392-5A patent/BRPI0512392B1/pt active IP Right Grant
- 2005-06-21 DK DK05766584.6T patent/DK1768691T3/da active
- 2005-06-21 MX MXPA06015037A patent/MXPA06015037A/es active IP Right Grant
- 2005-06-21 EP EP12188025.6A patent/EP2545934B1/en not_active Expired - Lifetime
- 2005-06-21 SI SI200531724T patent/SI1768691T1/sl unknown
- 2005-06-21 PL PL05766584T patent/PL1768691T3/pl unknown
- 2005-06-21 ES ES05766584T patent/ES2422173T3/es not_active Expired - Lifetime
- 2005-06-21 PT PT57665846T patent/PT1768691E/pt unknown
- 2005-06-21 AU AU2005265266A patent/AU2005265266B2/en not_active Expired
- 2005-06-21 EP EP05766584.6A patent/EP1768691B1/en not_active Expired - Lifetime
- 2005-06-21 CA CA2571542A patent/CA2571542C/en not_active Expired - Lifetime
- 2005-06-21 WO PCT/US2005/021770 patent/WO2006010004A2/en not_active Ceased
- 2005-06-21 CN CN200580024585XA patent/CN1997383B/zh not_active Expired - Lifetime
-
2006
- 2006-12-19 ZA ZA200610688A patent/ZA200610688B/en unknown
- 2006-12-19 IL IL180195A patent/IL180195A/en active IP Right Grant
-
2010
- 2010-01-27 US US12/694,427 patent/US20100152117A1/en not_active Abandoned
-
2013
- 2013-06-14 CY CY20131100486T patent/CY1114307T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2100051I1 (hu) | Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére | |
| IL187382A0 (en) | Bicyclic derivatives as modulators of ion channels | |
| GB0515353D0 (en) | Food | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| GEP20084550B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
| TNSN07005A1 (fr) | Analogues tetrapeptidiques | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| DK2321321T3 (da) | Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister | |
| TW200612905A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| IL193080A0 (en) | Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith | |
| TW200611702A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
| MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MXPA06011327A (es) | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. | |
| EA201070423A1 (ru) | Диарильные соединения оксадиазолов | |
| GB0625648D0 (en) | Compounds | |
| ZA200702375B (en) | Quinazolines useful as modulators of ion channels | |
| TW200738669A (en) | Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide | |
| IL205696A0 (en) | Heterocyclic derivatives, compositions comprising the same and uses thereof | |
| CY1114307T1 (el) | Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν | |
| TW200724140A (en) | Hydantoin compounds | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| TW200700064A (en) | Novel compounds | |
| TW200736227A (en) | New compounds III | |
| MX2010009753A (es) | Composiciones que contienen apoaecuorina y metodos de uso de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |